{"id":384105,"date":"2020-11-18T09:15:12","date_gmt":"2020-11-18T14:15:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=384105"},"modified":"2020-11-18T09:15:12","modified_gmt":"2020-11-18T14:15:12","slug":"correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/","title":{"rendered":"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19<\/b><\/p>\n<p>MIAMI&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nThe Phase number of the clinical trial in the first paragraph, first sentence of release should read: Phase I\/II (instead of Phase I\/I).\n<\/p>\n<p>\nThe updated release reads:\u00a0\n<\/p>\n<p class=\"bwalignc\"><b>ORGANICELL ANNOUNCES ADDITIONAL SITE FOR PHASE I\/II CLINICAL TRIAL OF ZOFIN\u2122 FOR TREATMENT OF COVID-19<\/b><\/p>\n<p>\nOrganicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I\/II clinical trial for the use of its Zofin\u2122 therapeutic in treatment of COVID-19.\n<\/p>\n<p>\nThis multi-center, randomized, double-blinded, placebo-controlled phase I\/II clinical trial is being conducted to investigate the safety and potential efficacy of intravenous infusion of Zofin\u2122 for the treatment of moderate to severe acute respiratory syndrome (SARS) related to COVID-19. The study will be enrolling 20 participants. As of November 17, 2020, several patients have already begun treatment at Larkin Hospital South, located in South Miami, Florida.\n<\/p>\n<p>\n\u201cThe addition of this clinical trial site is another step towards determining whether to apply for FDA approval for the use of Zofin\u2122 as a COVID-19 treatment, and increases our capacity for participating patients in order to finalize this clinical trial by year\u2019s end,\u201d said Albert Mitrani, Chief Executive Officer of Organicell.\n<\/p>\n<p>\n\u201cTo date, we have successfully enrolled several patients who have begun treatment in this trial, with no reported serious adverse events. We are looking forward to continued progress as we enroll additional patients in the coming weeks. Most of all, we are eager to begin enrollment at Larkin Community Hospital North this week,\u201d said Dr. Luis Mendez-Mulet, Infectious Disease Specialist at Alternative Research Associates and Larkin Community Hospital.\n<\/p>\n<p>\n\u201cWe are excited to sign on Larkin Hospital North as a second clinical trial site. We look forward to working with their research team as we advance our trial for using Zofin\u2122 to treat moderate to severe acute respiratory syndrome due to COVID-19,\u201d said Dr. Maria Ines Mitrani, Chief Science Officer of Organicell.\n<\/p>\n<p><b>About Organicell Regenerative Medicine, Inc.: <\/b><\/p>\n<p>\nOrganicell Regenerative Medicine, Inc. is a clinical-stage biopharmaceutical company that harnesses the power of nanoparticles to develop innovative biological therapeutics for the treatment of degenerative diseases. The Company\u2019s proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring microRNAs, without the addition or combination of any other substance or diluent. Based in South Florida, the Company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Maria Ines Mitrani, Chief Science Officer. To learn more, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Forganicell.com%2F&amp;esheet=52330598&amp;newsitemid=20201118005302&amp;lan=en-US&amp;anchor=https%3A%2F%2Forganicell.com%2F&amp;index=1&amp;md5=f46b317b78223068220ae357c7f7b286\">https:\/\/organicell.com\/<\/a>.\n<\/p>\n<p><b>About Larkin Hospital <\/b><\/p>\n<p>\nLarkin Community Hospital is an integrated healthcare delivery system accredited by the Joint Commission with locations in South Miami, Hialeah and Hollywood, Florida. Our network of acute care hospitals provides a complete continuum of healthcare services, including a full range of inpatient and outpatient services, home health agencies, Skilled Nursing facilities, Rehab centers and Assisted Living facilities in Miami-Dade and Broward County. To learn more, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Flarkinhospital.com%2F&amp;esheet=52330598&amp;newsitemid=20201118005302&amp;lan=en-US&amp;anchor=http%3A%2F%2Flarkinhospital.com%2F.&amp;index=2&amp;md5=0631d4276f6ab2ed2e60eb0dc9a884ec\">http:\/\/larkinhospital.com\/.<\/a><\/p>\n<p><b>About Zofin\u2122:<\/b><\/p>\n<p>\nZofin\u2122 is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles\/nanoparticles derived from perinatal tissues. Zofin\u2122 is currently being tested in a phase I\/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin\u2122 for the treatment of moderate to SARS related to COVID-19 infection vs placebo.\n<\/p>\n<p><b>Forward-Looking Statements: <\/b><\/p>\n<p>\nCertain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as \u201cwill,\u201d \u201cbelieves,\u201d \u201cexpects,\u201d \u201cpotential\u201d or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally and other known and unknown risks and uncertainties, including the risk factors discussed in the Company&#8217;s periodic reports that are filed with the SEC and available on the SEC&#8217;s website (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52330598&amp;newsitemid=20201118005302&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.sec.gov&amp;index=3&amp;md5=f9cff30b5886a92e0752fcc398e25241\">http:\/\/www.sec.gov<\/a>). You are cautioned not to place undue reliance on these forward-looking statements All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201118005302\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201118005302\/en\/<\/a><\/span><\/p>\n<p>\nJeffrey Freedman<br \/>\n<br \/>RooneyPartners<br \/>\n<br \/>646-432-0191<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:jfreedman@rooneyco.com\">jfreedman@rooneyco.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Florida United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Hospitals Clinical Trials Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201118005302\/en\/814004\/3\/logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19 MIAMI&#8211;(BUSINESS WIRE)&#8211; The Phase number of the clinical trial in the first paragraph, first sentence of release should read: Phase I\/II (instead of Phase I\/I). The updated release reads:\u00a0 ORGANICELL ANNOUNCES ADDITIONAL SITE FOR PHASE I\/II CLINICAL TRIAL OF ZOFIN\u2122 FOR TREATMENT OF COVID-19 Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I\/II clinical trial for the use of its Zofin\u2122 therapeutic in treatment of COVID-19. This multi-center, randomized, double-blinded, placebo-controlled &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-384105","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19 MIAMI&#8211;(BUSINESS WIRE)&#8211; The Phase number of the clinical trial in the first paragraph, first sentence of release should read: Phase I\/II (instead of Phase I\/I). The updated release reads:\u00a0 ORGANICELL ANNOUNCES ADDITIONAL SITE FOR PHASE I\/II CLINICAL TRIAL OF ZOFIN\u2122 FOR TREATMENT OF COVID-19 Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I\/II clinical trial for the use of its Zofin\u2122 therapeutic in treatment of COVID-19. This multi-center, randomized, double-blinded, placebo-controlled &hellip; Continue reading &quot;CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-18T14:15:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\\\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19\",\"datePublished\":\"2020-11-18T14:15:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/\"},\"wordCount\":981,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/\",\"name\":\"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\\\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-11-18T14:15:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\\\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19 - Market Newsdesk","og_description":"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19 MIAMI&#8211;(BUSINESS WIRE)&#8211; The Phase number of the clinical trial in the first paragraph, first sentence of release should read: Phase I\/II (instead of Phase I\/I). The updated release reads:\u00a0 ORGANICELL ANNOUNCES ADDITIONAL SITE FOR PHASE I\/II CLINICAL TRIAL OF ZOFIN\u2122 FOR TREATMENT OF COVID-19 Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that it is now enrolling patients at an additional site, Larkin Hospital North located in Hialeah, Florida for its Phase I\/II clinical trial for the use of its Zofin\u2122 therapeutic in treatment of COVID-19. This multi-center, randomized, double-blinded, placebo-controlled &hellip; Continue reading \"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-18T14:15:12+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19","datePublished":"2020-11-18T14:15:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/"},"wordCount":981,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/","name":"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-11-18T14:15:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201118005302r2&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/correcting-and-replacing-organicell-announces-additional-site-for-phase-i-ii-clinical-trial-of-zofin-for-treatment-of-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CORRECTING and REPLACING Organicell Announces Additional Site for Phase I\/II Clinical Trial of Zofin\u2122 for Treatment of COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384105","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=384105"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/384105\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=384105"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=384105"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=384105"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}